Jafron Biomedical Co.,Ltd. (SHE:300529)

China flag China · Delayed Price · Currency is CNY
20.69
+0.52 (2.58%)
Jan 23, 2026, 3:04 PM CST
-23.74%
Market Cap16.02B
Revenue (ttm)2.04B
Net Income (ttm)481.79M
Shares Out774.36M
EPS (ttm)0.63
PE Ratio32.87
Forward PE21.28
Dividend0.80 (3.87%)
Ex-Dividend DateMay 26, 2025
Volume6,400,644
Average Volume5,534,374
Open20.51
Previous Close20.17
Day's Range20.20 - 20.70
52-Week Range19.19 - 27.73
Beta0.48
RSI58.29
Earnings DateApr 28, 2026

About Jafron Biomedical

Jafron Biomedical Co.,Ltd. engages in the research and development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machine; and other products, such as JM hemodialyzer, DNA230, disinfectant, hemodialysis concentrate, resin bandage, online hemodialysis B powder bag/buc... [Read more]

Sector Healthcare
Founded 1989
Employees 2,797
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300529
Full Company Profile

Financial Performance

In 2024, Jafron Biomedical's revenue was 2.68 billion, an increase of 39.27% compared to the previous year's 1.92 billion. Earnings were 820.20 million, an increase of 87.91%.

Financial Statements